Perrigo Company plc (0Y5E.L)
USD 26.0
(-2.11%)
USD 26.0
(-2.11%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 151.9 Million USD | -12.09% |
| 2022 | 172.8 Million USD | -69.88% |
| 2021 | 573.7 Million USD | -38.47% |
| 2020 | 932.4 Million USD | 54.24% |
| 2019 | 604.5 Million USD | 155.6% |
| 2018 | 236.5 Million USD | -60.46% |
| 2017 | 598.2 Million USD | 129.91% |
| 2016 | -1.99 Billion USD | -367.48% |
| 2015 | 747.6 Million USD | 31.85% |
| 2014 | 567 Million USD | -16.51% |
| 2013 | 679.1 Million USD | 19.3% |
| 2012 | 569.22 Million USD | 16.12% |
| 2011 | 490.2 Million USD | 45.94% |
| 2010 | 335.89 Million USD | 35.82% |
| 2009 | 247.3 Million USD | 25.23% |
| 2008 | 197.48 Million USD | 100.38% |
| 2007 | 98.55 Million USD | -11.48% |
| 2006 | 111.33 Million USD | 133.69% |
| 2005 | -330.47 Million USD | -421.17% |
| 2004 | 102.89 Million USD | 20.8% |
| 2003 | 85.17 Million USD | -2.09% |
| 2002 | 86.99 Million USD | 116.9% |
| 2001 | 40.11 Million USD | 28.05% |
| 2000 | 31.32 Million USD | 74.03% |
| 1999 | 18 Million USD | 129.13% |
| 1998 | -61.8 Million USD | -185.71% |
| 1997 | 72.1 Million USD | 5.72% |
| 1996 | 68.2 Million USD | -9.67% |
| 1995 | 75.5 Million USD | -16.3% |
| 1994 | 90.2 Million USD | 22.72% |
| 1993 | 73.5 Million USD | 36.36% |
| 1992 | 53.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 23.5 Million USD | 250.64% |
| 2024 Q2 | 64.8 Million USD | 175.74% |
| 2023 Q4 | -15.6 Million USD | -125.12% |
| 2023 Q2 | 56.8 Million USD | 17.11% |
| 2023 Q1 | 48.5 Million USD | 56.45% |
| 2023 FY | 151.9 Million USD | -12.09% |
| 2023 Q3 | 62.1 Million USD | 9.33% |
| 2022 Q1 | 21.7 Million USD | -53.53% |
| 2022 FY | 172.8 Million USD | -69.88% |
| 2022 Q3 | 56.2 Million USD | 209.77% |
| 2022 Q4 | 31 Million USD | -44.84% |
| 2022 Q2 | -51.2 Million USD | -335.94% |
| 2021 Q3 | 438.3 Million USD | 448.13% |
| 2021 FY | 573.7 Million USD | -38.47% |
| 2021 Q1 | 51.4 Million USD | 198.47% |
| 2021 Q2 | -125.9 Million USD | -344.94% |
| 2021 Q4 | 46.7 Million USD | -89.35% |
| 2020 Q1 | 145.7 Million USD | 2211.59% |
| 2020 Q4 | -52.2 Million USD | 45.34% |
| 2020 Q3 | -95.5 Million USD | -181.35% |
| 2020 FY | 932.4 Million USD | 54.24% |
| 2020 Q2 | 117.4 Million USD | -19.42% |
| 2019 FY | 604.5 Million USD | 155.6% |
| 2019 Q3 | 54.4 Million USD | -1.09% |
| 2019 Q4 | -6.9 Million USD | -112.68% |
| 2019 Q1 | 102.3 Million USD | -4.84% |
| 2019 Q2 | 55 Million USD | -46.24% |
| 2018 Q4 | 107.5 Million USD | 188.11% |
| 2018 FY | 236.5 Million USD | -60.46% |
| 2018 Q2 | 94.7 Million USD | -39.41% |
| 2018 Q1 | 156.3 Million USD | -1.45% |
| 2018 Q3 | -122 Million USD | -228.83% |
| 2017 Q1 | 128.5 Million USD | 130.67% |
| 2017 Q2 | 148.8 Million USD | 15.8% |
| 2017 Q3 | 162.4 Million USD | 9.14% |
| 2017 Q4 | 158.6 Million USD | -2.34% |
| 2017 FY | 598.2 Million USD | 129.91% |
| 2016 Q4 | -419 Million USD | 72.35% |
| 2016 FY | -1.99 Billion USD | -367.48% |
| 2016 Q2 | 238.3 Million USD | 178.44% |
| 2016 Q1 | -303.8 Million USD | -222.85% |
| 2016 Q3 | -1.51 Billion USD | -735.84% |
| 2015 Q1 | 199.2 Million USD | 8.03% |
| 2015 Q4 | -94.1 Million USD | -149.89% |
| 2015 FY | 747.6 Million USD | 31.85% |
| 2015 Q2 | 226.9 Million USD | 13.91% |
| 2015 Q3 | 188.6 Million USD | -16.88% |
| 2014 Q3 | 137.2 Million USD | -30.53% |
| 2014 FY | 567 Million USD | -16.51% |
| 2014 Q1 | 103.3 Million USD | 19.28% |
| 2014 Q2 | 197.5 Million USD | 91.19% |
| 2014 Q4 | 184.4 Million USD | 34.4% |
| 2013 Q3 | 179.7 Million USD | -0.2% |
| 2013 Q4 | 86.6 Million USD | -51.81% |
| 2013 Q1 | 178.6 Million USD | 9.0% |
| 2013 FY | 679.1 Million USD | 19.3% |
| 2013 Q2 | 180.06 Million USD | 0.82% |
| 2012 FY | 569.22 Million USD | 16.12% |
| 2012 Q3 | 156.57 Million USD | -2.71% |
| 2012 Q2 | 160.93 Million USD | 10.18% |
| 2012 Q1 | 146.07 Million USD | -9.09% |
| 2012 Q4 | 163.85 Million USD | 4.65% |
| 2011 Q1 | 122.91 Million USD | -7.05% |
| 2011 FY | 490.2 Million USD | 45.94% |
| 2011 Q4 | 160.66 Million USD | 58.21% |
| 2011 Q3 | 101.55 Million USD | -17.63% |
| 2011 Q2 | 123.28 Million USD | 0.3% |
| 2010 Q3 | 111.76 Million USD | 44.12% |
| 2010 Q4 | 132.23 Million USD | 18.32% |
| 2010 Q1 | 87.3 Million USD | 3.36% |
| 2010 Q2 | 77.55 Million USD | -11.17% |
| 2010 FY | 335.89 Million USD | 35.82% |
| 2009 Q1 | 71.89 Million USD | 18.5% |
| 2009 Q3 | 86.56 Million USD | 55.91% |
| 2009 Q4 | 84.46 Million USD | -2.43% |
| 2009 FY | 247.3 Million USD | 25.23% |
| 2009 Q2 | 55.52 Million USD | -22.77% |
| 2008 Q4 | 60.67 Million USD | 3.4% |
| 2008 Q1 | 95.12 Million USD | 94.77% |
| 2008 Q2 | 41.83 Million USD | -56.02% |
| 2008 Q3 | 58.68 Million USD | 40.26% |
| 2008 FY | 197.48 Million USD | 100.38% |
| 2007 Q4 | 48.84 Million USD | 6.06% |
| 2007 FY | 98.55 Million USD | -11.48% |
| 2007 Q1 | 23.53 Million USD | -10.82% |
| 2007 Q3 | 46.04 Million USD | 100.9% |
| 2007 Q2 | 22.92 Million USD | -2.59% |
| 2006 FY | 111.33 Million USD | 133.69% |
| 2006 Q4 | 26.38 Million USD | 2.63% |
| 2006 Q3 | 25.71 Million USD | 22.79% |
| 2006 Q2 | 20.93 Million USD | -31.02% |
| 2006 Q1 | 30.35 Million USD | -22.78% |
| 2005 Q2 | -5.41 Million USD | 98.56% |
| 2005 FY | -330.47 Million USD | -421.17% |
| 2005 Q4 | 39.3 Million USD | 89.63% |
| 2005 Q3 | 20.72 Million USD | 482.52% |
| 2005 Q1 | -375.82 Million USD | -1656.29% |
| 2004 Q2 | 12.26 Million USD | -53.72% |
| 2004 Q1 | 26.51 Million USD | -31.62% |
| 2004 FY | 102.89 Million USD | 20.8% |
| 2004 Q4 | 24.14 Million USD | -9.3% |
| 2004 Q3 | 26.62 Million USD | 117.02% |
| 2003 Q1 | 22.52 Million USD | -14.5% |
| 2003 Q4 | 38.77 Million USD | 52.97% |
| 2003 Q2 | 6.57 Million USD | -70.79% |
| 2003 Q3 | 25.34 Million USD | 285.24% |
| 2003 FY | 85.17 Million USD | -2.09% |
| 2002 Q3 | 31.06 Million USD | 184.55% |
| 2002 Q1 | 29.86 Million USD | 15.88% |
| 2002 FY | 86.99 Million USD | 116.9% |
| 2002 Q4 | 26.34 Million USD | -15.19% |
| 2002 Q2 | 10.91 Million USD | -63.45% |
| 2001 Q4 | 25.77 Million USD | 26.01% |
| 2001 Q1 | 14.33 Million USD | -30.05% |
| 2001 FY | 40.11 Million USD | 28.05% |
| 2001 Q2 | 8.6 Million USD | -39.95% |
| 2001 Q3 | 20.45 Million USD | 137.65% |
| 2000 Q1 | 9.98 Million USD | -47.16% |
| 2000 FY | 31.32 Million USD | 74.03% |
| 2000 Q3 | 16.43 Million USD | 206.0% |
| 2000 Q2 | -15.5 Million USD | -255.23% |
| 2000 Q4 | 20.48 Million USD | 24.66% |
| 1999 Q3 | 17.8 Million USD | 1212.5% |
| 1999 FY | 18 Million USD | 129.13% |
| 1999 Q1 | 19.3 Million USD | 42.96% |
| 1999 Q2 | -1.6 Million USD | -108.29% |
| 1999 Q4 | 18.9 Million USD | 6.18% |
| 1998 Q4 | 13.5 Million USD | 203.05% |
| 1998 FY | -61.8 Million USD | -185.71% |
| 1998 Q2 | -128.5 Million USD | -825.99% |
| 1998 Q1 | 17.7 Million USD | -30.86% |
| 1998 Q3 | -13.1 Million USD | 89.81% |
| 1997 FY | 72.1 Million USD | 5.72% |
| 1997 Q3 | 22.8 Million USD | 62.86% |
| 1997 Q2 | 14 Million USD | -24.73% |
| 1997 Q1 | 18.6 Million USD | -15.84% |
| 1997 Q4 | 25.6 Million USD | 12.28% |
| 1996 Q3 | 19.5 Million USD | 926.32% |
| 1996 Q2 | 1.9 Million USD | -90.4% |
| 1996 Q1 | 19.8 Million USD | -13.54% |
| 1996 FY | 68.2 Million USD | -9.67% |
| 1996 Q4 | 22.1 Million USD | 13.33% |
| 1995 FY | 75.5 Million USD | -16.3% |
| 1995 Q3 | 23.6 Million USD | 129.13% |
| 1995 Q2 | 10.3 Million USD | -47.45% |
| 1995 Q4 | 22.9 Million USD | -2.97% |
| 1995 Q1 | 19.6 Million USD | -7.55% |
| 1994 Q4 | 21.2 Million USD | -13.11% |
| 1994 FY | 90.2 Million USD | 22.72% |
| 1994 Q3 | 24.4 Million USD | 29.1% |
| 1994 Q1 | 21.9 Million USD | -12.75% |
| 1994 Q2 | 18.9 Million USD | -13.7% |
| 1993 FY | 73.5 Million USD | 36.36% |
| 1993 Q1 | 18.5 Million USD | -4.15% |
| 1993 Q2 | 18.4 Million USD | -0.54% |
| 1993 Q3 | 24.3 Million USD | 32.07% |
| 1993 Q4 | 25.1 Million USD | 3.29% |
| 1992 Q4 | 19.3 Million USD | 12.21% |
| 1992 Q1 | 14.4 Million USD | 5.11% |
| 1992 Q2 | 13.4 Million USD | -6.94% |
| 1992 Q3 | 17.2 Million USD | 28.36% |
| 1992 FY | 53.9 Million USD | 0.0% |
| 1991 Q4 | 13.7 Million USD | -84.27% |
| 1991 Q3 | 87.1 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 189.785% |
| Dynavax Technologies Corporation | -37.02 Million USD | 510.23% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 2982.9% |
| Illumina, Inc. | -1.06 Billion USD | 114.21% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 97.785% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 132.982% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 101.079% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 92.317% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 237.323% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 96.247% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 440.072% |
| Waters Corporation | 817.67 Million USD | 81.423% |
| Biogen Inc. | 1.29 Billion USD | 88.287% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 155.437% |
| Evolus, Inc. | -49.23 Million USD | 408.533% |
| Adicet Bio, Inc. | -152.03 Million USD | 199.909% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 225.026% |
| bluebird bio, Inc. | -244.26 Million USD | 162.187% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 197.645% |
| FibroGen, Inc. | -281.81 Million USD | 153.901% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 88.748% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 436.977% |
| Homology Medicines, Inc. | -48.25 Million USD | 414.786% |
| Geron Corporation | -193.94 Million USD | 178.322% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 153.832% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 306.684% |
| Myriad Genetics, Inc. | -123.7 Million USD | 222.797% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 250.654% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 129.478% |
| Zoetis Inc. | 3.06 Billion USD | 95.051% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 415.145% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 86.029% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 21.879% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 96.474% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 487.965% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 142.942% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 155.035% |
| Verastem, Inc. | -92.08 Million USD | 264.958% |
| Nektar Therapeutics | -137.42 Million USD | 210.533% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 165.524% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 256.024% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 156.716% |
| OPKO Health, Inc. | -157.02 Million USD | 196.739% |
| Exelixis, Inc. | 170.88 Million USD | 11.11% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 39.458% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -41.589% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 372.437% |
| uniQure N.V. | -282.87 Million USD | 153.699% |
| Imunon, Inc. | -21.03 Million USD | 822.287% |
| Blueprint Medicines Corporation | -486.27 Million USD | 131.237% |
| Insmed Incorporated | -709.62 Million USD | 121.406% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 55.002% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 138.801% |
| TG Therapeutics, Inc. | 20.63 Million USD | -636.199% |
| Incyte Corporation | 620.52 Million USD | 75.521% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 120.911% |